|
| 37442722 | Long-term Recurrence Rates of Low-risk Non-muscle-invasive Bladder Cancer-How Long Is Cystoscopic Surveillance Necessary? | Eur Urol Focus | 2024 |
| 38010224 | A multidisciplinary discussion of BladderPath. | Can Urol Assoc J | 2024 |
| 37980689 | Second TURB, restaging TURB or repeat TURB in primary T1 non-muscle invasive bladder cancer: impact on prognosis? | Int Urol Nephrol | 2024 |
| 36272946 | Re: Management, Surveillance Patterns, and Costs Associated with Low-grade Papillary Stage Ta Non-muscle-invasive Bladder Cancer Among Older Adults, 2004-2013. | Eur Urol | 2023 |
| 37541276 | Radical cystectomy vs trimodality therapy for muscle-invasive bladder cancer: further extensive evaluation needed - Authors' reply. | Lancet Oncol | 2023 |
| 37730609 | Clinical and dosimetric outcomes of image-guided, dose-painted radiotherapy in muscle invasive bladder cancer. | Radiat Oncol | 2023 |
| 37606994 | Increasing trend of utilising active surveillance for Gleason Score 7â¿¿(3â¿¿+â¿¿4) prostate cancer. | BJU Int | 2023 |
| 37187202 | Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. | Lancet Oncol | 2023 |
| 37211455 | Development, multi-institutional external validation, and algorithmic audit of an artificial intelligence-based Side-specific Extra-Prostatic Extension Risk Assessment tool (SEPERA) for patients undergoing radical prostatectomy: a retrospective cohort study. | Lancet Digit Health | 2023 |
| 37439809 | Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial. | Clin Cancer Res | 2023 |
| 37103562 | Cost of Bladder Cancer Care: A Single-center Comparison of Radical Cystectomy and Trimodal Therapy. | Urol Pract | 2023 |
| 36748180 | Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy. | BJU Int | 2023 |
| 36841687 | Erratum to "European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel" [Eur. Urol. 79(4) (2021) 480-488]. | Eur Urol | 2023 |
| 36683418 | Low-volume grade group 2 prostate cancer candidates for active surveillance: a radical prostatectomy retrospective analysis. | Scand J Urol | 2023 |
| 36639336 | Validating the total cancer location density metric for stratifying patients with low-risk localized prostate cancer at higher risk of grade group reclassification while on active surveillance. | Urol Oncol | 2023 |
| 36670042 | Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive Spectrum. | Eur Urol Oncol | 2023 |
| 34812723 | Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Markov microsimulation model. | Can Urol Assoc J | 2022 |
| 35507051 | Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy. | Eur Radiol | 2022 |
| 35703460 | Association Between Surgeon and Anesthesiologist Sex Discordance and Postoperative Outcomes: A Population-based Cohort Study. | Ann Surg | 2022 |
| 35577750 | T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non-muscle-invasive Bladder Cancer Spectrum. | Eur Urol Focus | 2022 |
| 35852425 | Comparison of Micro-US and Multiparametric MRI for Prostate Cancer Detection in Biopsy-Naive Men. | Radiology | 2022 |
| 35393232 | The prognostic value of urinary cytology after trimodal therapy (TMT) for muscle-invasive bladder cancer. | Urol Oncol | 2022 |
| 36031465 | Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer. | Int J Radiat Oncol Biol Phys | 2022 |
| 35151601 | Combining CAPRA-S With Tumor IDC/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer Patients. | Clin Genitourin Cancer | 2022 |
| 34906411 | Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. | Urol Oncol | 2022 |
| 32152437 | Long-term use of 5-alpha-reductase inhibitors is safe and effective in men on active surveillance for prostate cancer. | Prostate Cancer Prostatic Dis | 2021 |
| 33685838 | Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. | Eur Urol | 2021 |
| 33599318 | Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis. | Prostate | 2021 |
| 33900880 | MRI-guided Focused Ultrasound Ablation for Localized Intermediate-Risk Prostate Cancer: Early Results of a Phase II Trial. | Radiology | 2021 |
| 33529137 | MRI-guided Focused Ultrasound Ablation for Localized Intermediate-Risk Prostate Cancer: Early Results of a Phase II Trial. | Radiology | 2021 |
| 35099374 | Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Abridged version. | Can Urol Assoc J | 2021 |
| 34851968 | Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study. | PLoS One | 2021 |
| 34716314 | Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse. | Nat Commun | 2021 |
| 34131332 | 100 years of Bacillus Calmette-Guérin immunotherapy: from cattle to COVID-19. | Nat Rev Urol | 2021 |
| 33938798 | Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text. | Can Urol Assoc J | 2021 |
| 34032510 | Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer. | Radiology | 2021 |
| 34254464 | Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223. | Cancer Med | 2021 |
| 34134928 | Characterization and management of NMIBC recurrences after TMT: a matched cohort analysis. | Urol Oncol | 2021 |
| 33132108 | Switching Cancers: A Systematic Review Assessing the Role of Androgen Suppressive Therapy in Bladder Cancer. | Eur Urol Focus | 2021 |
| 33419683 | European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. | Eur Urol | 2021 |
| 33037772 | Novel use of an old compound? Urologist-led Bacille Calmette-Guérin vaccine trials in the prevention of coronavirus disease 2019. | BJU Int | 2021 |
| 32636160 | Natural History of Renal Angiomyolipoma Favors Surveillance as an Initial Approach. | Eur Urol Focus | 2021 |
| 31348742 | Are there differences among bacillus Calmette-Guérin (BCG) strains regarding their clinical efficacy in the treatment of non-muscleinvasive bladder cancer? The jury is still out but the answer is likely no. | Can Urol Assoc J | 2020 |
| 34337479 | Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not. | Eur Urol Open Sci | 2020 |
| 32081560 | A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade. | Urol Oncol | 2020 |
| 31863617 | Salvage radical prostatectomy following focal therapy: functional and oncological outcomes. | BJU Int | 2020 |
| 32037144 | Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434-5. | Eur Urol | 2020 |
| 33263367 | Trimodal therapy in muscle invasive bladder cancer management. | Minerva Urol Nefrol | 2020 |
| 32969766 | Reply by Authors. | J Urol | 2020 |
| 32712139 | Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure. | Urol Oncol | 2020 |